Altomonte M[au] - Search Results

Year	Number of Results
1983	1
1984	3
1986	3
1988	1
1989	2
1991	2
1992	2
1993	4
1995	5
1996	4
1997	5
1998	2
1999	4
2000	3
2001	4
2002	6
2003	9
2004	2
2005	3
2006	3
2007	3
2009	2
2010	5
2011	2
2012	2
2013	4
2014	1
2015	1
2016	1
2017	2
2018	4
2020	3
2021	2
2022	2

1

Challenges in lung cancer therapy during the COVID-19 pandemic.

Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, Altomonte M, Vegni V, Gridelli C, Reck M, Rizvi N, Maio M. Calabrò L, et al. Among authors: altomonte m. Lancet Respir Med. 2020 Jun;8(6):542-544. doi: 10.1016/S2213-2600(20)30170-3. Epub 2020 Apr 9. Lancet Respir Med. 2020. PMID: 32278368 Free PMC article. No abstract available.

2

Epigenetic immunomodulation of hematopoietic malignancies.

Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabrò L, Maio M. Gattei V, et al. Among authors: altomonte m. Semin Oncol. 2005 Oct;32(5):503-10. doi: 10.1053/j.seminoncol.2005.07.006. Semin Oncol. 2005. PMID: 16210091 Review.

3

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.

Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardhana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Giacomo AMD. Maio M, et al. Among authors: altomonte m. Clin Cancer Res. 2020 Aug 15;26(16):4201-4205. doi: 10.1158/1078-0432.CCR-20-1657. Epub 2020 Jun 15. Clin Cancer Res. 2020. PMID: 32540850

4

Biology and clinical applications of CD40 in cancer treatment.

Fonsatti E, Maio M, Altomonte M, Hersey P. Fonsatti E, et al. Among authors: altomonte m. Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002. Semin Oncol. 2010. PMID: 21074067 Review.

5

Epigenetic targets for immune intervention in human malignancies.

Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Maio M, et al. Among authors: altomonte m. Oncogene. 2003 Sep 29;22(42):6484-8. doi: 10.1038/sj.onc.1206956. Oncogene. 2003. PMID: 14528272 Review.

6

European approach to antibody-based immunotherapy of melanoma.

Altomonte M, Maio M. Altomonte M, et al. Semin Oncol. 2002 Oct;29(5):471-8. doi: 10.1053/sonc.2002.35242. Semin Oncol. 2002. PMID: 12407512 Review.

7

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.

Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Fonsatti E, et al. Among authors: altomonte m. Cardiovasc Res. 2010 Apr 1;86(1):12-9. doi: 10.1093/cvr/cvp332. Epub 2009 Oct 7. Cardiovasc Res. 2010. PMID: 19812043 Review.

8

Endoglin (CD105): a target for anti-angiogenetic cancer therapy.

Fonsatti E, Altomonte M, Arslan P, Maio M. Fonsatti E, et al. Among authors: altomonte m. Curr Drug Targets. 2003 May;4(4):291-6. doi: 10.2174/1389450033491073. Curr Drug Targets. 2003. PMID: 12699349 Review.

9

Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.

Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo AM, Altomonte M, Maio M. Sigalotti L, et al. Among authors: altomonte m. Semin Oncol. 2005 Oct;32(5):473-8. doi: 10.1053/j.seminoncol.2005.07.005. Semin Oncol. 2005. PMID: 16210088 Review.

10

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.

Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Fonsatti E, et al. Among authors: altomonte m. Oncogene. 2003 Sep 29;22(42):6557-63. doi: 10.1038/sj.onc.1206813. Oncogene. 2003. PMID: 14528280 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results